(Q28192002)

https://api.crossref.org/works/10.1517/13543784.10.10.1831

Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.10.10.1831

Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Intranasal sumatriptan for the acute treatment of migraine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Oral sumatriptan-associated transmural myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Cardiac arrest and myocardial infarction immediately after sumatriptan injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Transmural myocardial infarction with sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Vasospasm-induced myocardial infarction with sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Sumatriptan-induced stroke in sagittal sinus thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Fatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Ischemic colitis and sumatriptan use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Pregnancy outcome following prescription for sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Naratriptan: biological profile in animal models relevant to migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Naratriptan Long-Term Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Pilot study of MK-462 in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Inappropriate use of sumatriptan: population based register and interview study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Coronary side-effect potential of current and prospective antimigraine drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Variation in the placebo effect in randomised controlled trials of analgesics: all is as blind as it seems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Placebo effect and clinical trials in migraine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

The prophylactic value of propranolol in angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Propranolol in the management of recurrent migraine: a meta-analytic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Nifedipine versus propranolol for the initial prophylaxis of migraine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Comparison of mefenamic acid and propranolol with placebo in migraine prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Amitriptyline in Migraine Prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Migraine prophylaxis. A comparison of propranolol and amitriptyline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Alpha-dihydroergocryptine in the prophylaxis of migraine: a multicenter double-blind study versus flunarizine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Divalproex sodium in migraine prophylaxis: a dose-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Migraine prophylaxis with divalproex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Lamotrigine in the prophylactic treatment of migraine aura--a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Efficacy of gabapentin in migraine prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Effectiveness of amitriptyline in the prophylactic management of childhood headaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Methodology of clinical trials of sumatriptan in migraine and cluster headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Comparison of the Efficacy of Zolmitriptan and Sumatriptan: Issues in Migraine Trial Design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831

Treatment of Mild Headache in Disabled Migraine Sufferers: Results of the Spectrum Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1831